Edited sentence: "Settlement" of this suit with Cephalon was hardly a risky endeavor for the generic manufacturers, as it was Cephalon which agreed to pay Provigil's alleged infringers in excess of a billion dollars -- if they agreed NOT to market generics for Provigil during their period of exclusivity.In effect, Cephalon was able to extend its exclusive right to manufacture Provigil even though Cephalon's patent for Provigil had already run out.Recently, the purpose of the exclusivity "bonus" provided for by the Hatch-Waxman Amendments was turned on its head when the original patent holder, Cephalon, instituted patent infringement suit against all companies holding generic exclusivity rights to manufacture modafinil, the generic name for Cephalon's still-profitable stimulant drug, Provigil